COMP <GO>
MDT vs UNH // FREE CASH FLOW YIELD
Medtronic plc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: MDT 7
— UNH 8
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $96.54 (-0.59%) • MKT CAP: $124.22B
fcf-yield
4.37%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
fcf-yield
6.48%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDT VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDT | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 65.00% | 88.57% | -23.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.80% | 11.47% | -3.67 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.4x | 16.4x | +0.95 | UNH | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.37% | 6.48% | -2.11 | UNH | /fcf-yield <GO> |
| Operating Margin | 17.80% | 4.82% | +12.98 | MDT | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 3.14% | -3.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 8.40% | 6.46% | +1.94 | MDT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.93% | 2.28% | +0.65 | MDT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.08 | 3.12 | -0.04 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | MDT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.74% | -0.14 | MDT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.5 | 56.0 | +4.49 | MDT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.33 | +0.58 | MDT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 17.1x | +122.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $124.22B | $364.66B | -$240.44B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDT REV | UNH REV | MDT GROSS % | UNH GROSS % | MDT FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $36.36B | $447.57B | 65.0% | 88.7% | $5.43B | $16.07B |
| FY 2024 | $33.54B | $400.28B | 65.3% | 88.3% | $5.18B | $20.70B |
| FY 2023 | $32.36B | $371.62B | 44.0% | 89.6% | $5.33B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDT // BETA 0.91
UNH // BETA 0.33